Does the media prefer RXRX or SYRE?

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 6 mentions for Spyre Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.07 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RXRX or RYTM?

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 3 mentions for Rhythm Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or RXRX?

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 4 mentions for Lantheus. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Lantheus' score of 0.54 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or RXRX?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 9 mentions for Mirum Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Mirum Pharmaceuticals' score of 0.92 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.80 +0.33 (+9.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.79 -0.01 (-0.26%)

As of 07:59 PM Eastern

Compare

RXRX vs. PTGX, SYRE, RYTM, LNTH, and MIRM

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Protagonist Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A
Protagonist Therapeutics	$46.02M	143.64	-$130.15M	-$1.81	N/A

Recursion Pharmaceuticals presently has a consensus price target of $8.10, indicating a potential upside of 113.16%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 12.09%. Given Recursion Pharmaceuticals' higher probable upside, research analysts clearly believe Recursion Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Protagonist Therapeutics has a net margin of -154.88% compared to Recursion Pharmaceuticals' net margin of -842.95%. Protagonist Therapeutics' return on equity of -17.76% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 7 mentions for Protagonist Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Protagonist Therapeutics' score of 0.72 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 6 mentions for Spyre Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Spyre Therapeutics' score of 0.07 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Recursion Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A
Spyre Therapeutics	$890K	7,657.53	-$155.20M	-$2.08	N/A

Recursion Pharmaceuticals currently has a consensus target price of $8.10, indicating a potential upside of 113.16%. Spyre Therapeutics has a consensus target price of $91.33, indicating a potential upside of 16.38%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Spyre Therapeutics' return on equity of -42.88% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Spyre Therapeutics	N/A	-42.88%	-27.76%

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Spyre Therapeutics beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Recursion Pharmaceuticals presently has a consensus price target of $8.10, indicating a potential upside of 113.16%. Rhythm Pharmaceuticals has a consensus price target of $131.81, indicating a potential upside of 50.45%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 3 mentions for Rhythm Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A
Rhythm Pharmaceuticals	$189.76M	31.64	-$196.54M	-$3.13	N/A

Recursion Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

Summary

Recursion Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Recursion Pharmaceuticals' net margin of -842.95%. Lantheus' return on equity of 29.32% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Lantheus presently has a consensus target price of $101.86, indicating a potential downside of 0.94%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 113.16%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 4 mentions for Lantheus. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Lantheus' score of 0.54 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A

Summary

Lantheus beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Recursion Pharmaceuticals' net margin of -842.95%. Mirum Pharmaceuticals' return on equity of -11.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 9 mentions for Mirum Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat Mirum Pharmaceuticals' score of 0.92 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.82	-$23.36M	-$13.61	N/A
Recursion Pharmaceuticals	$74.68M	26.96	-$644.76M	-$1.20	N/A

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus price target of $137.64, suggesting a potential upside of 48.82%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 113.16%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Recursion Pharmaceuticals beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01B	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-3.17	18.12	23.87	24.36
Price / Sales	26.96	303.59	521.52	117.01
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.78	3.95	9.99	6.73
Net Income	-$644.76M	$75.85M	$3.56B	$337.03M
7 Day Performance	10.47%	-1.13%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-22.61%	23.03%	28.76%	33.98%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	2.9377 of 5 stars	$3.80 +9.5%	$8.10 +113.2%	-21.0%	$1.84B	$74.68M	N/A	400	Insider Trade High Trading Volume
PTGX Protagonist Therapeutics	2.0072 of 5 stars	$99.19 -2.8%	$115.21 +16.2%	+86.9%	$6.56B	$46.02M	N/A	120	Insider Trade
SYRE Spyre Therapeutics	1.9131 of 5 stars	$74.05 -0.4%	$90.25 +21.9%	+343.7%	$6.45B	$890K	N/A	73	News Coverage Analyst Forecast Insider Trade
RYTM Rhythm Pharmaceuticals	2.8218 of 5 stars	$87.84 -2.6%	$131.81 +50.1%	+29.0%	$6.18B	$189.76M	N/A	140	Analyst Forecast
LNTH Lantheus	2.0809 of 5 stars	$103.00 +9.0%	$99.71 -3.2%	+29.0%	$6.15B	$1.54B	24.82	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. PTGX, SYRE, RYTM, LNTH, and MIRM

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. PTGX, SYRE, RYTM, LNTH, and MIRM

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Which has higher valuation and earnings, RXRX or PTGX?

Do analysts prefer RXRX or PTGX?

Do institutionals and insiders have more ownership in RXRX or PTGX?

Is RXRX or PTGX more profitable?

Which has more risk and volatility, RXRX or PTGX?

Does the media prefer RXRX or PTGX?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Does the media prefer RXRX or SYRE?

Which has more volatility and risk, RXRX or SYRE?

Which has preferable valuation & earnings, RXRX or SYRE?

Do analysts prefer RXRX or SYRE?

Is RXRX or SYRE more profitable?

Do institutionals & insiders have more ownership in RXRX or SYRE?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Do analysts rate RXRX or RYTM?

Is RXRX or RYTM more profitable?

Does the media refer more to RXRX or RYTM?

Do institutionals and insiders have more ownership in RXRX or RYTM?

Which has preferable valuation and earnings, RXRX or RYTM?

Which has more volatility and risk, RXRX or RYTM?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Do insiders and institutionals have more ownership in LNTH or RXRX?

Which has more risk & volatility, LNTH or RXRX?

Is LNTH or RXRX more profitable?

Do analysts recommend LNTH or RXRX?

Does the media favor LNTH or RXRX?

Which has higher valuation & earnings, LNTH or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Is MIRM or RXRX more profitable?

Does the media favor MIRM or RXRX?

Which has preferable earnings and valuation, MIRM or RXRX?

Do institutionals & insiders have more ownership in MIRM or RXRX?

Which has more volatility & risk, MIRM or RXRX?

Do analysts recommend MIRM or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools